All 9 patients in a phase 1 trial testing a neoantigen-targeting personalized cancer vaccine in renal cell carcinoma had no recurrence at data cutoff.
In a phase 1 trial (NCT02950766), neoantigen-targeting personalized cancer vaccines (PCV) with or without ipilimumab (Yervoy) elicited anti-cancer immune responses in a small cohort of patients with fully resected clear cell renal cell carcinoma (RCC), according to findings published in Nature.1
Data revealed that the PCVs were immunogenic in all 9 patients enrolled and treated on trial. Furthermore, there were no RCC recurrences observed with a median follow-up of 40.2 months after surgery. Additionally, at a median follow-up of 34.7 months following vaccine administration, the median disease-free survival (DFS) was not reached.
Safety data revealed that the most common…